Popular
LFCR · Medicine & biotech · U.S.

Lifecore Biomedical

Fills and packages injectable medicines for other drug companies.

Company Health

17
/100
Fragile
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $30 of every $100 in sales.
Is it growing?
14 of 25 · Okay
Sales grew about 5% a year over the last 3 years.
Can it handle what it owes?
3 of 25 · Poor
Its business used cash last year, and it owes $80 of every $100 it owns.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in: $11 of every $100 in sales.

Who owns it

1 of 23 own it · Nobody changed their stake
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Lifecore Biomedical’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales fell from $160 million in the year to May 2020 to $129 million in the year to May 2025, and it made a profit in 1 of the 6 years.
FY2025
Sales
$129 million
Loss
$38.7 million

Spare cash each year

It spent more cash than it brought in every year: $13.6 million more in the year to May 2025.
FY2025
Cash shortfall
$13.6 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment. Some years don’t say what it spent, so those bars may be a little high.

What it owns and what it owes

At the end of May 2025 it owned $239 million, including $8.27 million in cash, and owed $192 million.

Key facts

From its yearly report for the year to May 2025.
Sales
$129 million
Loss
$38.7 million
Cash shortfall
$13.6 million
Cash in the bank
$8.27 million
Everything it owes
$192 million
Year ends
May
Money shown in
U.S. dollars
Latest yearly report
10-KT, filed Mar 16, 2026
Figures from Lifecore Biomedical’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy